Basilea Pharmaceutica (XSWX:BSLN) Total Current Liabilities: CHF49.2 Mil (As of Dec. 2025)


XSWX:BSLN Basilea Pharmaceutica Ltd XSWX:BSLN
61 GF Score
Price CHF54.30
GF Value CHF57.51
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Basilea Pharmaceutica Total Current Liabilities?

Basilea Pharmaceutica XSWX:BSLN +2.26% 61 Total Current Liabilities is CHF49.2 Mil as of Dec. 2025. GuruFocus rates XSWX:BSLN with a GF Score™ of 61/100 and a GF Value™ of CHF57.51 (Fairly Valued). The stock has 2 warning signs investors should review.

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Basilea Pharmaceutica's total current liabilities for the quarter that ended in Dec. 2025 was CHF49.2

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Basilea Pharmaceutica Total Current Liabilities Related Terms

Basilea Pharmaceutica Total Current Liabilities Historical Data

* Premium members only.

The historical data trend for Basilea Pharmaceutica's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Basilea Pharmaceutica Total Current Liabilities Chart

Basilea Pharmaceutica Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 174.41 74.85 47.59 45.56 49.22

Basilea Pharmaceutica Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 47.59 37.78 45.56 34.39 49.22
XSWX:BSLN
61GF Score
Basilea Pharmaceutica Ltd XSWX:BSLN
Total Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Basilea Pharmaceutica Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Basilea Pharmaceutica's Total Current Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=15.058+2.062
+Other Current Liabilities+Current Deferred Liabilities
=32.096+0
=49.2

Basilea Pharmaceutica's Total Current Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=15.058+2.062
+Other Current Liabilities+Current Deferred Liabilities
=32.096+0
=49.2

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

What does a Total Current Liabilities of CHF49.2 Mil mean?
Basilea Pharmaceutica (XSWX:BSLN) has a Total Current Liabilities of CHF49.2 Mil as of Dec. 2025. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Basilea Pharmaceutica and its competitors.
Is Basilea Pharmaceutica's Total Current Liabilities too high?
Basilea Pharmaceutica's current Total Current Liabilities is CHF49.2 Mil. Overall, Basilea Pharmaceutica has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Basilea Pharmaceutica's Total Current Liabilities compare to VRTX and REGN?
Basilea Pharmaceutica's Total Current Liabilities of CHF49.2 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Biotechnology company?
A good Total Current Liabilities depends on the Biotechnology industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Basilea Pharmaceutica and its competitors. Basilea Pharmaceutica's current Total Current Liabilities is CHF49.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Basilea Pharmaceutica stock overvalued right now?
Based on GuruFocus' analysis, Basilea Pharmaceutica (XSWX:BSLN) is currently considered Fairly Valued. The stock's GF Value™ is CHF57.51, compared to a current price of CHF54.30 — trading 5.6% below its estimated fair value. The current Total Current Liabilities is CHF49.2 Mil. Basilea Pharmaceutica's overall GF Score™ is 61/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For Basilea Pharmaceutica (XSWX:BSLN), the current Total Current Liabilities is CHF49.2 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Basilea Pharmaceutica (XSWX:BSLN) Overvalued in 2026?

Based on GuruFocus' analysis, Basilea Pharmaceutica stock appears to be undervalued. The current stock price of CHF54.30 is trading 5.6% below its estimated GF Value™ of CHF57.51. GuruFocus considers Basilea Pharmaceutica to be Fairly Valued.

Key valuation signals for XSWX:BSLN:

  • Total Current Liabilities: CHF49.2 Mil
  • GF Value™: CHF57.51 vs. price of CHF54.30 (5.6% below fair value)
  • GF Score™: 61/100 with 2 warning signs

No single metric tells the full story. See the XSWX:BSLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Basilea Pharmaceutica Business Description

Address Hegenheimermattweg 167b, Allschwil, CHE, 4123
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.
61GF Score

Get the complete analysis for XSWX:BSLN

Total Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF54.30
Price
CHF57.51
GF Value